United States - English - NLM (National Library of Medicine)

e5 pharma, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. phenobarbital is a schedule iv drug. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fata

United States - English - NLM (National Library of Medicine)

sterling-knight pharmaceuticals, llc - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 97.2 mg - a. sedative b. anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the sam

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 32.4 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intox

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - phenobarbital sodium (unii: sw9m9bb5k3) (phenobarbital - unii:yqe403bp4d) - phenobarbital sodium 65 mg in 1 ml - - sedative. sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. however, thyrotoxic individuals occasionally react poorly to barbiturates. - hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see clinical pharmacology ). -  preanesthetic. - long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatme

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 20 mg in 5 ml - a. sedative b. anticonvulsant- for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. phenobarbital is a schedule iv drug. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administrations in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree to physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fa

United States - English - NLM (National Library of Medicine)

direct rx - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 64.8 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxic

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - phenobarbital 16.2 mg - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance – phenobarbital is a schedule iv drug. dependence – barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intox

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - phenobarbital - oral tablet - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - phenobarbital - oral tablet - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - phenobarbital - oral tablet - 30mg